Low libido affects approximately 40% of women, yet until recently, treatment options remained limited. If you’ve been weighing on-demand libido treatments like Libida™ against Vyleesi, you’re asking the right questions—because how a treatment works matters just as much as whether it works.
Key Takeaways
- On-demand libido treatments work through the brain’s desire pathways, offering an alternative to daily medications or hormonal interventions
- Libida™ is the only formulation combining bremelanotide with oxytocin, addressing both the neurochemical spark of desire and emotional connection pathways
- Vyleesi received FDA approval in 2019 as an injectable treatment for premenopausal women with HSDD
- Sublingual delivery (Libida™) eliminates the need for injections, while injectable options like Vyleesi offer documented bioavailability
- Cost per use varies significantly between treatment options depending on coverage
- Duration of effect differs: Libida™ effects may last 24-72 hours, while Vyleesi’s half-life is approximately 2.7 hours
- Both treatments are non-hormonal and can complement hormone restoration therapy like Oestra™ for comprehensive care
Libida™ is a brain-based libido booster for women – no hormones, meds, or injections. One dissolvable tablet to bring the spark back, on your terms.
HSA/FSA Eligible •
Free shipping • Cancel anytime
Understanding On-Demand Treatments for Low Female Libido
Female sexual desire is complex. Unlike the straightforward blood-flow mechanics of male arousal, women’s sexuality involves intricate interplay between brain chemistry, emotional readiness, hormonal status, and relational connection.
Hypoactive Sexual Desire Disorder (HSDD) affects an estimated 6 million premenopausal women in the United States alone. The condition is characterized by persistently low sexual desire that causes significant personal distress—not simply a temporary dip in interest due to stress or relationship factors.
On-demand treatments represent a shift from daily medications toward targeted, situational support. Rather than altering brain chemistry continuously, these treatments activate desired pathways when needed, typically 30-60 minutes before anticipated intimacy.
The brain-first approach makes scientific sense. Sexual desire originates in the hypothalamus, where melanocortin receptors (specifically MC4R) influence motivation, anticipation, and arousal. By targeting these receptors directly, on-demand treatments work upstream of physical arousal—addressing the “wanting” that precedes the physical response.
Who Benefits from On-Demand Treatments?
On-demand libido support may help women who:
- Identify with statements like “my spark is gone” or “I love my partner, but I never feel like it”
- Have addressed hormonal factors but still experience flat desire
- Want flexibility rather than daily medication commitment
- Prefer a brain-first, non-hormonal approach
- Experience HSDD or persistent low libido that causes distress
Libida™: A Dual-Pathway Approach to Women’s Desire
Libida™ represents Inner Balance’s prescription formulation, designed specifically for women whose desire feels muted, disconnected, or missing. What distinguishes Libida™ is its dual-pathway approach—the first women-first libido solution to combine bremelanotide with oxytocin.
How Libida™ Works: Bremelanotide and Oxytocin
Bremelanotide activates melanocortin receptors (MC4R) in the hypothalamus. This activation boosts dopamine—the neurotransmitter associated with motivation, reward, and anticipation. The result is increased sexual thoughts, heightened motivation for intimacy, and improved arousal response. Bremelanotide is the same FDA-approved active ingredient used in injectable treatments for desire.
Oxytocin, often called the “bonding hormone,” activates emotional-safety pathways that support connection, closeness, and relational warmth. For many women, emotional readiness is inseparable from physical desire. Oxytocin supports the sense of relaxation into intimacy that allows genuine arousal to emerge.
Together, these two pathways address how women’s sexuality actually works—not just the neurochemical spark, but the emotional context that shapes desire.
Key Features of Libida™
- Route: Tiny sublingual lozenge (no injection needed)
- Timing: On demand, approximately 45-60 minutes before intimacy
- Duration: Effects may last 24-72 hours
- Type: Brain-acting peptide plus oxytocin combination
- Non-hormonal: Compatible with any hormonal status; can be used with or without Oestra™
Clinical Evidence for Bremelanotide
The bremelanotide component of Libida™ has demonstrated significant clinical benefits in randomized controlled trials:
- Increased desire and arousal
- More satisfying sexual events
- Reduced distress related to low desire
- Restored fantasies and responsiveness
These studies, conducted for FDA approval of the injectable form, showed meaningful improvements across multiple measures of female sexual function.
What Makes Libida™ Different
Libida™ is compounded for off-label use under clinician guidance. This compounding approach allows for the innovative combination of bremelanotide and oxytocin—a dual-pathway formulation not available in any FDA-approved product.
The sublingual route offers practical advantages for women who prefer to avoid injections. The tablet dissolves under the tongue, allowing absorption through the oral mucosa.
Vyleesi: The FDA-Approved Injectable Option
Vyleesi (bremelanotide injection) received FDA approval in June 2019 for the treatment of acquired, generalized HSDD in premenopausal women. It remains the only FDA-approved on-demand injectable treatment that targets desire through melanocortin receptor activation.
How Vyleesi Works
Vyleesi contains bremelanotide, the same active ingredient in Libida™. The medication is administered via subcutaneous injection using an autoinjector pen approximately 45 minutes before anticipated sexual activity.
Pharmacokinetic data shows injectable bremelanotide achieves:
- Peak concentration (Cmax): 72.8 ng/mL
- Time to peak (Tmax): Approximately 1 hour
- Half-life: 2.7 hours
- Bioavailability: 100% via subcutaneous injection
Administering Vyleesi
Patients self-administer Vyleesi using a pre-filled autoinjector. The injection is given in the abdomen at least 45 minutes before anticipated sexual activity. The FDA recommends no more than 8 doses per month and only one dose within 24 hours.
Clinical Trial Results
In clinical trials involving over 1,200 participants, Vyleesi demonstrated meaningful improvements. In the pivotal trials, approximately 25% of patients treated with Vyleesi experienced a meaningful increase in their sexual desire score, compared to about 17% of those who took a placebo. The treatment also showed:
- Approximately one additional satisfying sexual event per month
- Significant decrease in distress scores
- Statistically significant improvements across multiple endpoints
Side Effect Profile
The most commonly reported side effects in clinical trials included:
- Nausea (40% of participants)
- Flushing
- Injection site reactions
- Headache
Approximately 13% of participants required anti-nausea medication. A small percentage (roughly 1%) experienced focal hyperpigmentation (skin darkening) on areas such as the gums, face, or breasts, which may not fully resolve after discontinuation.
Libida vs. Vyleesi: Key Differences in Delivery and Formulation
While both treatments target the same brain pathways for desire, several distinctions merit consideration when choosing between them.
Sublingual vs. Injectable: Ease of Use
Libida™ uses sublingual administration—a small lozenge dissolves under the tongue. This needle-free approach appeals to women who experience anxiety around injections or prefer a more discrete method of administration.
Vyleesi requires subcutaneous injection via autoinjector. For women comfortable with self-injection (similar to insulin or fertility medications), this presents a straightforward process. The injection route provides complete systemic absorption through subcutaneous administration.
Oxytocin’s Role in Libida™
The addition of oxytocin in Libida™ represents a fundamental difference in treatment philosophy. While bremelanotide addresses the dopamine-driven “spark” of desire, oxytocin supports the emotional readiness and connection that many women identify as central to their arousal.
This dual-pathway approach acknowledges that female desire often requires both neurochemical activation and emotional safety—elements that can’t be separated in real-world intimacy.
Duration of Effect
Libida™ effects may last 24-72 hours, offering extended flexibility for spontaneity. Vyleesi has a shorter half-life of approximately 2.7 hours, meaning most of the medication is cleared within about 13–14 hours.
Regulatory Status
Vyleesi holds FDA approval specifically for premenopausal women with acquired, generalized HSDD. Libida™ is a compounded prescription formulated under clinician guidance, allowing for the innovative combination of bremelanotide and oxytocin.
Understanding the Cost: Comparing Value
Cost considerations vary significantly depending on insurance coverage and chosen treatment.
Libida™ Pricing
Libida™ offers several purchasing options:
- One-time purchase: $249 for 10 tablets
- Monthly subscription: $199/month for 10 tablets
- Best value subscription: $249 for 20 tablets ($279 charged every 2 months)
- Quarterly option: $299 for 30 tablets (charged every 3 months)
This translates to approximately $10-$25 per use, depending on the purchasing plan, with HSA/FSA eligibility.
Vyleesi Cost Considerations
Vyleesi pricing depends heavily on insurance status:
- With manufacturer program: Around $99 for 4 doses (for eligible patients)
- Retail price without assistance: Approximately $250-$442 for 4 doses
- Insurance coverage: A significant percentage of commercial plans cover Vyleesi, with potential low copays for eligible patients
Per-use cost ranges from approximately $25 per dose (with manufacturer assistance) to higher amounts at retail pricing.
Who Is the Ideal Candidate for Each Treatment?
Libida™: When Desire Needs More Than Hormones Alone
Libida™ is designed for women whose:
- Desire feels muted, disconnected, or absent despite overall wellness
- Hormones have been addressed (through Oestra™ or other HRT) but desire still feels flat
- Connection and emotional closeness are central to their arousal patterns
- Lifestyle includes situations where needle-free administration is preferred
Women who prefer to avoid injections, want extended-duration effects, or resonate with the dual-pathway approach targeting both desire and connection may find Libida™ aligns with their needs.
Vyleesi: For Diagnosed HSDD
Vyleesi is specifically indicated for premenopausal women with acquired, generalized HSDD. Ideal candidates:
- Have received an HSDD diagnosis from a healthcare provider
- Are comfortable with self-injection
- Have insurance coverage that includes Vyleesi
- Prefer an FDA-approved treatment with documented pharmacokinetics
Women who prioritize FDA regulatory approval and documented bioavailability via injection may find Vyleesi’s clinical validation reassuring.
Contraindications for Both
Neither treatment is appropriate during pregnancy, breastfeeding, or in cases of uncontrolled hypertension or certain cardiovascular conditions. Both should be prescribed under clinician guidance with appropriate medical screening.
Clinical Evidence and Effectiveness
Understanding the Research
The active ingredient bremelanotide was evaluated in two large phase 3 clinical trials supporting its FDA approval for premenopausal women with acquired, generalized HSDD.
- Statistically significant improvements in desire scores
- Increased number of satisfying sexual events
- Reduced distress related to low libido
- Restored sexual fantasies and responsiveness
These trials enrolled over 1,200 participants and met primary and secondary endpoints for efficacy.
Effectiveness Rates
Market analysis suggests both bremelanotide-based treatments achieve effectiveness in approximately 50-60% of women who try them. This rate reflects the complexity of female sexual desire.
The Oxytocin Variable
Libida™’s addition of oxytocin represents an innovative approach addressing both dopamine-driven motivation and oxytocin-supported emotional connection—reflecting emerging understanding of female sexuality’s complexity.
Inner Balance’s Approach to Women’s Holistic Health
Understanding libido in isolation misses the bigger picture. Desire exists within the context of overall hormonal health, emotional wellbeing, and relational connection.
Complementary Inner Balance Products
Oestra™ Hormone Enrichment Cream addresses foundational hormonal balance through bioidentical estradiol and progesterone delivered vaginally. This delivery method offers significantly higher bioavailability compared to oral pills by bypassing first-pass liver metabolism.
For women whose low libido stems partly from hormone imbalance—particularly declining estrogen and progesterone during perimenopause or menopause—addressing hormonal foundations may be essential before or alongside brain-targeted treatments.
BodyMatched™ Anti-Aging Face Cream extends hormone-smart care to skin health, using bioidentical estriol to target hormonally aging skin.
The Inner Balance Care Model
Inner Balance operates through board-certified physicians licensed in all 50 states. The telehealth model provides:
- Personalized treatment plans
- Ongoing dose adjustments based on symptoms
- Unlimited access to healthcare experts
- Care team guidance throughout treatment
This symptom-based approach—treating how you feel rather than just lab numbers—reflects current understanding that women’s hormonal health requires individualized care.
Positioning Libida™ in Comprehensive Care
Libida™ is designed to complement hormonal optimization. For women whose desire lags even when hormones are balanced, Libida™ offers targeted neurological support. For women beginning their hormone restoration with Oestra™, Libida™ can be added if desire doesn’t fully return with hormonal balance alone.
This ecosystem approach—addressing hormonal foundations (Oestra™), neurological desire (Libida™), and external skin health (BodyMatched™)—represents comprehensive support for women’s vitality at every level.
Making the Right Choice
Choosing between on-demand libido treatments is deeply personal. What works for one woman may not suit another—and that’s exactly why multiple options exist.
For women who resonate with a dual-pathway approach addressing both desire and emotional connection, prefer needle-free administration, and want extended-duration effects, Libida™ offers a thoughtfully designed solution.
For women who prioritize FDA approval, documented bioavailability via injection, and potential insurance coverage, Vyleesi provides a clinically validated option.
Addressing low libido starts with recognizing that your experience is real, treatable, and worthy of attention. You deserve to feel like yourself again—and today’s options make that possible.
Libida™ is a brain-based libido booster for women – no hormones, meds, or injections. One dissolvable tablet to bring the spark back, on your terms.
HSA/FSA Eligible •
Free shipping • Cancel anytime
Frequently Asked Questions
What is the main difference between Libida™ and Vyleesi?
Both contain bremelanotide, which activates melanocortin receptors in the brain to boost desire. The key differences are delivery method (sublingual tablet versus injection) and formulation—Libida™ uniquely combines bremelanotide with oxytocin to address both the neurochemical spark of desire and emotional connection pathways. Vyleesi is FDA-approved, while Libida™ is a compounded prescription formulated under clinician guidance.
Can Libida™ be used by women already on hormone therapy?
Yes. Libida™ is non-hormonal and compatible with any hormonal status. It can be used alongside Oestra™ or other hormone restoration therapy. Many women find that addressing both hormonal foundations and brain-based desire pathways provides more comprehensive support than either approach alone.
How quickly do Libida™ and Vyleesi start working?
Both treatments work relatively quickly compared to daily medications. Libida™ should be taken approximately 45-60 minutes before anticipated intimacy. Vyleesi is administered at least 45 minutes before sexual activity. Effects from Libida™ may last 24-72 hours, while Vyleesi has a shorter duration of action.
Are there any side effects to consider?
Vyleesi’s clinical trials reported nausea in approximately 40% of participants, along with flushing, injection site reactions, and headache. A small percentage experienced skin darkening that may not fully resolve. As a sublingual formulation, Libida™ may have a different side effect profile; discuss potential effects with your prescribing clinician. Neither treatment is appropriate during pregnancy, breastfeeding, or with uncontrolled hypertension.
Is Libida™ FDA-approved?
Libida™ is a compounded prescription formulated under clinician guidance. It contains the same FDA-approved active ingredient (bremelanotide) used in Vyleesi, the FDA-approved injectable treatment for desire. The compounding approach allows for the innovative combination of bremelanotide and oxytocin not available in any FDA-approved product.
